Total adverse events · Adults with acute asthma
Combination inhaled therapy probably leads to higher total adverse events compared with SABA alone (moderate certainty).
1 finding from 1 review
Adverse events · adults with cystic fibrosis and with the F508del/MF genotype
1 finding from 1 review
Adverse events · adults with cystic fibrosis and with the F508del/MF genotype
1 finding from 1 review
Adverse events, · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes adverse Events, compared with no neoadjuvant treatment (very low certainty).
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events · people with conversion disorder according to DSM‐IV or ICD‐10 criteria
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events: hypertension · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: five to… showed no clear difference in adverse events: hypertension compared with three months (moderate certainty).
1 finding from 1 review
Adverse events grade 3 to 5 Range of
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher grade III to V adverse events compared with ADT only (low certainty).
1 finding from 1 review
Adverse events · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype
1 finding from 1 review
Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC
It is very uncertain whether summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi… changes any severe adverse events (grade 3 or higher) (G3+ SevAE) compared with chemotherapy (very low certainty).
1 finding from 1 review
Adverse events · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype
1 finding from 1 review
Adverse events incidence · patients with stable angina pectoris
It is very uncertain whether ranolazine (monotherapy) changes adverse events incidence compared with placebo (very low certainty).
1 finding from 1 review
Adverse eventsb · sudden sensorineural hearing loss
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
SAEs
It is very uncertain whether summary of findings of metformin monotherapy for adults with type 2… changes serious adverse events (SAE) compared with thiazolidinediones (very low certainty).
1 finding from 1 review
SAEs
1 finding from 1 review
SAEs
1 finding from 1 review
SAEs
1 finding from 1 review
Dropouts due to adverse events · anxiety and depression in children and adolescents with long‐term physical conditions
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: eye complications · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: five to… showed no clear difference in adverse events: eye complications compared with three months (moderate certainty).
1 finding from 1 review